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CHAPTER I 
 
INTRODUCTION 
. 
Parkinson disease (PD) is the second most common neurodegenerative disorder 
in adults and was originally defined as a motor disease based on the four hallmark 
characteristics: resting tremor, bradykinesia, rigidity, and postural instability.1 However, it 
has since been realized that individuals with PD are affected by many other symptoms. 
Non-motor symptoms of PD include dementia, pain, mood disorders, sleep difficulties, 
and autonomic dysfunction. Not all symptoms are present for each individual diagnosed 
with PD, but the number and severity of symptoms tend to accumulate over time. The 
average age at diagnosis of PD is 70.5 years and most frequently occurs after the age of 
60.2  
The clinical expression and physiological systems involved in Parkinson disease 
are also complex, suggesting variability in the etiology. Development of PD in an 
individual has been attributed to environmental factors, genetic factors, and interactions 
between the two, although we still understand only a small part of all the components in 
play.3-6 Many environmental factors have been implicated in PD, but only a few are 
consistent across studies (pesticides as a risk factor, smoking and caffeine as protective 
factors).3,7,8 In addition, an abundance of genetic risk factors have been identified, and 
many have been replicated and confirmed by subsequent studies. Loci have been 
identified that act under autosomal dominant (e.g. SNCA, LRRK2) and autosomal 
recessive (e.g. PRKN, DJ1, PINK1) models, and that function as strong risk factors for 
development of the disease and other associations with common polymorphisms (e.g. 
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variants in GBA, MAPT).4,9-11  At least 13 loci have been confirmed as PD-related loci 
and they have been identified through linkage, candidate gene, genome-wide 
association, and exome sequencing studies. These results are encouraging and exciting; 
however, there is still a large portion of the genetic component of PD that remains to be 
uncovered. In light of this, we have undertaken a study in an isolated founder population, 
from mid-western Amish communities in Ohio and Indiana, and conducted genome-wide 
association and linkage analyses to detect additional PD-related loci.  
The Amish population is a promising population to study the genetic risk of PD 
for several reasons. The first PD-related loci were identified in genetically isolated 
founder populations.12 We hypothesize that the genetics of PD may be less 
heterogeneous in the Amish due to the shared ancestry and minimal gene flow. Also, the 
Amish share a very homogenous lifestyle, including minimal caffeine and tobacco use, 
due to cultural and religious beliefs. This homogenous background may allow us to more 
easily detect genetic effects by reducing confounding effects of environmental factors. 
We have analyzed 798 individuals, who can all be connected into one 4,998-member 
pedigree. In this dataset we see a higher average kinship coefficient among pairs of 
affected individuals (.0177) compared to pairs of unaffected individuals (.0149). We 
performed a Wilcoxon rank-sum (Mann Whitney) test and found this difference to be 
statistically significant (p < 1 x 10-4), strongly suggesting that PD is heritable in the Amish 
and likely a valuable population to uncover future knowledge of the underlying genetics 
of PD.   
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CHAPTER II 
 
METHODS 
 
Subjects 
 Methods for ascertainment were reviewed and approved by the individual 
Institutional Review Boards of the respective institutions. Informed consent was obtained 
from participants recruited from Amish communities with which we have had established 
working relationship for over 10 years. These communities are in Elkhart, LaGrange, 
Adams, and surrounding Indiana counties, and Holmes and surrounding Ohio counties. 
To date we have enrolled over 2,200 Amish individuals with 32 of these diagnosed with 
PD.   
Clinical Evaluation 
The spectrum of clinical symptoms for this pedigree was previously 
described.13,14 A standardized interview for PD was conducted by a board-certified 
genetic counselor or genetic study research associate with participating individuals or a 
knowledgeable family informant. Individuals were screened for a history of encephalitis, 
dopamine-blocking medication exposure within one year before diagnosis, symptoms of 
normal pressure hydrocephalus (dementia, gait difficulty, and urinary incontinence), or a 
clinical course with unusual features suggestive of atypical or secondary parkinsonism. 
Individuals with a positive symptom history of PD and apparently unaffected individuals 
(mostly siblings) were personally examined by a board-certified neurologist with 
subspecialty training in movement disorders, and many have been examined more than 
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once to ensure the diagnoses are accurate over time. At these secondary interviews, 
participants were evaluated for a history of exposure to substances known or suspected 
to cause parkinsonism, including heavy metals and pesticides. Participants were 
classified as affected, unaffected or unknown, using published diagnosis criteria based 
on clinical history and neurologic examination.1 Affected individuals had at least two 
cardinal signs of PD (resting tremor, bradykinesia, or rigidity) and no atypical features of 
parkinsonism. Individuals with unknown status had only one sign of PD, a history of 
atypical clinical features, or both. Unaffected individuals had no signs of PD. Age at 
onset was self-reported and defined as the age at which onset of the first symptom 
suggestive of PD was noted by the affected individual. Levodopa responsiveness was 
determined based on physician and patient observations. Individuals with uncertain 
symptom benefit or who never received levodopa therapy were classified as having an 
unknown response. 
The severity of extrapyramidal signs and symptoms were evaluated by Hoehn-Yahr 
staging15 and the Unified Parkinson Disease Rating Scale (UPDRS-motor subscale) 
UPDRS-III16. When available, reports of brain imaging studies were reviewed to confirm 
the absence of hydrocephalus or vascular parkinsonism. Dementia was assessed by the 
memory-orientation-concentration test (Short-Blessed Test (SBT)).17 Diagnosis of 
progressive supranuclear palsy was determined from the NINDS-PSP International 
Workgroup clinical criteria.18 
Genotyping 
 Genotyping and quality control (QC) in this dataset were performed as described 
previously.19 Briefly, genome-wide genotyping was performed on 830 DNA samples 
using the Affymetrix 6.0 GeneChip ® Human Mapping 1 million array set (Affymetrix ®, 
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Inc Santa Clara, CA). DNA for this project was allocated by the respective DNA banks at 
both the Hussman Institute of Human Genomics (HIHG) at the University of Miami and 
the Center for Human Genetics Research (CHGR) at Vanderbilt University. Genomic 
DNA was quantitated via the ND-8000 spectrophotometer and DNA quality was 
evaluated via gel electrophoresis. The genomic DNA (250ng/5ul) samples were 
processed according to standard Affymetrix procedures for the processing of the 
Affymetrix 6.0 GeneChip array. The arrays were then scanned using the GeneChip 
Scanner 3000 7G operated by the Affymetrix® GeneChip® Command Console® (AGCC) 
software. The data were processed for genotype calling using the Affymetrix® Power 
Tools (APT) software using the Birdseed calling algorithm version 2.0 Affymetrix®, Inc 
Santa Clara, CA.  
Strict QC procedures were applied to both samples and SNPs to ensure the 
accuracy of our data prior to analyses. Sample QC included visualization of each DNA 
sample via agarose to ensure high quality samples prior to inclusion on the array and 
CEPH samples and duplicate samples plated across multiple arrays to check 
reproducibility across the arrays. Samples with call rates <95% were re-examined to 
ensure quality of genotypes; if the call rate for a sample was still <95% after this 
examination, we attempted to rerun the array with a new DNA sample. Nine samples 
failed at this point and were dropped due to low genotyping efficiency. The Anabaptist 
Genealogy DataBase (AGDB)20 was used to determine the relationships between 
individuals; three samples were excluded because they did not connect with the rest of 
the samples and the relationship of these individuals could not be accounted for in 
analyses. Samples with genetic sex (based on X chromosome heterozygosity rates) 
contrary to reported sex were excluded from analyses (16 samples). Sex mismatches 
were not correlated with genotyping efficiency or sample quality (DNA source, date of 
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collection, or degradation). Three samples appeared aberrantly connected in the 
pedigree based on genotype data and were also excluded. 
  SNP QC comprised checking call rates and minor allele frequencies (MAF). 
76,816 SNPs with call rates < 98% were dropped, along with 206,970 SNPs with MAF ≤ 
0.05. Due to the relatedness in this dataset we did not test SNPs for Hardy-Weinberg 
equilibrium. After this extensive QC, 798 samples and 622,812 SNPs were available for 
analysis. All samples are part of one 4,998-member pedigree with many 
consanguineous loops. The AGDB provided the pedigree information using an “all 
common paths” database query with all genotyped individuals. 
Statistical Analysis 
Association analysis was conducted using the Modified Quasi-Likelihood Score 
(MQLS)21 test for all SNPs. The MQLS test is analogous to a chi-square test for case-
control data, but adjusts for correlations among individuals based on pairwise kinship 
coefficients estimated from the pedigree structure. The MQLS test can be run on all 
samples without dividing the pedigree, which offers a great advantage by incorporating 
all pedigree data into a single analysis. Allele frequencies adjusted for relationships are 
also calculated by this program. Association analysis included all individuals in the 
4,998-member pedigree, including the 798 genotyped individuals (31 affected, 123 
unaffected, 647 unknown individuals). To test the validity of the MQLS test in our 
pedigree, we performed simulation studies using this same pedigree structure and null 
data to assess the type 1 error rate using MQLS for association. The genomic inflation 
factor for this analysis is 1.04. Type 1 error rates were not inflated (Cummings et al., 
submitted). 
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Linkage analyses were run using Merlin for autosomal chromosomes and MINX 
(Merlin in X) for the X chromosome.22 Due to the large size and substantial 
consanguinity of the pedigree, it was essential to cut the pedigree into smaller sub-
pedigrees that were computationally feasible to analyze. To do this we used PedCut23 to 
find an optimal set of sub-pedigrees with a bit size limit of 24 and a maximal number of 
subjects of interest in each pedigree. This procedure resulted in 10 sub-pedigrees (261 
individuals, 85 genotyped) for analysis with an average of 8.5 genotyped individuals (3 
genotyped affected) per sub-pedigree. (Table 1) Parametric two-point heterogeneity 
logarithm of the odds of linkage (HLOD) scores were computed using affecteds-only 
autosomal dominant and recessive models. Disease allele frequency was estimated at 1% 
under the dominant model and 20% under the recessive model. Under the dominant 
model, penetrances of 0 for no disease alleles and 0.0001 for one or two disease alleles 
were used. For the recessive model, penetrances of 0 for zero or one disease allele and 
0.0001 for two disease alleles were used.   
 
Sub-ped # genotyped (aff/unaff/unk) # not genotyped (aff/unaff/unk) 
1 3/8/2 0/1/2 
2 3/3/1 1/1/12 
3 3/6/0 0/0/12 
4 3/4/1 0/0/17 
5 3/4/1 0/0/14 
6 3/4/1 0/0/23 
7 3/5/2 0/0/23 
8 3/4/1 0/0/19 
9 3/3/1 0/0/27 
10 3/4/0 0/0/24 
 
Table 1 Number of individuals by sub-pedigree in linkage analyses 
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The number of SNPs and samples in our dataset prevented us from running the 
entire dataset in multipoint linkage analysis due to the complexity of the pedigree and 
extensive computational time. Regions showing evidence for linkage, i.e. containing at 
least one two-point HLOD ≥ 3.0, or with evidence for linkage (two-point HLOD ≥ 2.0) and 
association (MQLS p < 1 x 10-4) were followed up with parametric multipoint linkage 
analysis (also using Merlin). For the multipoint analyses, a seven megabase region 
surrounding each significant SNP(s) was used. If a clear LOD score peak was not 
observed in the results (e.g. the maximum LOD score was at one end, or the peak did 
not drop enough to define a 1-LOD-down support interval), we widened the region until 
we could define the complete peak. SNPs were pruned for linkage disequilibrium (LD) in 
each region so all pair-wise r2 values were < 0.16 between SNPs.24 The LD from the 
HapMap CEPH samples (parents only) was used for pruning. Initially, we chose to use 
this population for pruning because we were concerned that the consanguinity of the 
pedigree would cause us to overestimate LD between the SNPs and, subsequently, 
over-prune the data. Because the HapMap CEPH samples may not be an exact 
representation of LD in our Amish population, we further tested pruning using the data 
from this Amish dataset, but no significant difference was seen (data not shown). 
Because linkage analyses can be affected when breaking larger pedigrees into a series 
of smaller ones, we performed simulation studies assuming no linkage (e.g. null 
distribution) and using the same large pedigree structure and the same pedigree splitting 
method. We determined empirical cut-offs for significance in our linkage studies to 
maintain a nominal type I error rate. We found only 2.5% of the multipoint linkage scans 
generated a maximum HLOD > 3.0 (Cummings et al., submitted). Possible sub-
haplotypes and co-inheritance were determined manually and using Merlin. 
HaploPainter25 was used to draw sub-pedigrees with associated haplotypes.  
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Computations were performed using either the CHGR computational cluster or 
the Advanced Computing Center for Research and Education (ACCRE) cluster at 
Vanderbilt University. All map positions are listed in megabases (Mb) and refer to 
NCBI36/hg18, March 2006 positions. 
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CHAPTER III 
 
RESULTS 
 
Association Analysis 
622,812 SNPs were analyzed. No SNPs met a genome-wide significance cutoff 
of p < 5 x 10-8. (Figure 1) However, 70 SNPs representing 35 regions were identified at 
p < 1 x 10-4 across 16 chromosomes. 16 of the 35 regions had at least two SNPs 
significant at this level. The three most significant SNPs are located on chromosomes 
10q22.1 (COL13A1), 11q21 (CCDC82), and 15q25.1 (TMC3). (Table 2) All three SNPs 
are intronic.  
 
 
 
 
 
Figure 1 MQLS association results 
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Table 2 MQLS top results 
Chr SNP 
Map 
(Mb) 
MQLS 
p-value 
Gene 
Minor 
Allele 
MAF 
Aff 
MAF 
Unaff 
MAF 
Ov 
11q21 rs7118648 96.11 2.16 x 10
-7
 CCDC82 G 0.21 0.03 0.03 
15q25.1 rs3935740 81.63 2.31 x 10
-7
 TMC3 T 0.29 0.08 0.08 
10q22.1 rs17497526 71.58 5.50 x 10
-7
 COL13A1 G 0.42 0.15 0.15 
 
Linkage analysis 
Five SNPs had a two-point HLOD > 3.0, all under a recessive model. (Table 3) 
All SNPs had an alpha = 1. The highest HLOD (3.67) was seen on chromosome 5q23.2 
in an intron of the MEGF10 gene, with a minor allele frequency (MAF) adjusted for 
relatedness of 0.08 in unaffecteds and 0.27 in affecteds. Two other SNPs in this gene 
had an HLOD ≥ 2.5. Multipoint linkage analysis resulted in a peak HLOD of 1.81. 
Table 3 Top linkage (two-point) results 
Chr SNP 
Map 
(Mb) 
HLOD 
(DOM) 
HLOD 
(REC) 
Gene 
Minor 
Allele 
MAF 
Aff 
MAF 
Unaff 
MAF 
Ov 
5q23.2 rs17165041 126.70 2.51 3.67 MEGF10 G 0.28 0.08 0.08 
9q21.33 rs1439054 86.46 2.44 3.01 - G 0.26 0.10 0.09 
10p14 rs2186063 10.53 2.29 3.48 - T 0.46 0.18 0.18 
10p12.31 rs1926693 22.47 2.11 3.14 - G 0.16 0.06 0.06 
19q13.12 rs16970293 40.59 2.80 3.57 LOC100128682 C 0.15 0.04 0.04 
 
The next highest two-point HLOD was for rs16970293 on chromosome 19q13.12 
in a non-coding gene (LOC100128682). Multipoint linkage analysis in this region 
resulted in a peak HLOD of 1.95 (recessive model). Other significant SNPs were located 
on chromosomes 9q21.33, 10p14, and 10p12.31, all in intergenic regions. The multipoint 
HLOD for chromosome 9 was less than 1.0, suggesting further investigation was unlikely 
to uncover new knowledge about PD. However, multipoint analysis of the regions on 
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chromosome 10 showed a strong linkage peak 
(dominant HLOD 4.35). (Figure 2c, Table 4)  
Previously we identified linkage peaks 
in this population on chromosomes 6, 19, 21, 
and 22.13 In the current dataset with additional 
information, the two-point HLODs for these 
regions were between 1.5 and 1.99, and they 
did not meet our criteria for follow-up. However, 
because of the previous implication of these 
regions, we ran multipoint analyses. We did 
not see further evidence for linkage on 
chromosomes 19 and 22, but we did observe 
increased HLOD scores on chromosomes 6  
(dominant HLOD 4.02) (Figure 2b, Table 4) 
and 21 (dominant HLOD 2.83).  
 
Chr Map (Mb) Peak HLOD Model Alpha 1-LOD down SI (Mb) 
5q32 145.56 3.77 DOM 0.69 (142.08, 146.89) 
6q25.1 150.70 4.02 DOM 0.69 (150.59, 151.35) 
10p12.33 19.50 4.35 DOM 1.00 (16.40, 26.55) 
 
 
 
 
Table 4 Most significant multipoint linkage results (HLOD > 3) 
Figure 2 Multipoint HLOD scores 
for significant regions 
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Overlap 
To integrate the knowledge gained from performing linkage and association 
analyses, we looked at the overlap between the two. Six SNPs in five regions showed 
evidence of linkage (two-point HLOD ≥ 2.0) and association (MQLS p < 1 x 10-4). (Table 
5) Alpha values for the HLOD scores were equal to one. Two regions are in genes (FHIT, 
MEGF10), the others are intergenic. Multipoint linkage analyses were run for each of 
these regions. The region on chromosome 5q23.2 was analyzed as described above. 
Regions at 3p14.2, 4q34.2, and 18q11.2 showed no further evidence for linkage based 
on multipoint analysis. However, chromosome 5q31.3 showed greater evidence for 
linkage with an HLOD of 3.77 under a dominant model. (Figure 2a, Table 5)  
Table 5 Overlapping linkage (two-point) and association results 
Chr SNP 
Map 
(Mb) 
HLOD 
(DOM) 
HLOD 
(REC) 
MQLS 
p-value 
Gene 
Minor 
Allele 
MAF 
Aff 
MAF 
Unaff 
MAF 
Ov 
3p14.2 rs41355450 60.09 2.19 2.62 4.56 x 10
-5
 FHIT C 0.33 0.12 0.12 
4q34.2 rs6848215 177.72 1.55 2.35 8.16 x 10
-5
 - A 0.77 0.47 0.46 
5q23.2 rs17165041 126.70 2.51 3.67 2.97 x 10
-5
 MEGF10 G 0.28 0.08 0.08 
5q23.2 rs17673147 126.70 2.04 2.71 9.48 x 10
-6
 MEGF10 A 0.23 0.06 0.07 
5q31.3 rs17403174 142.93 1.66 2.10 9.59 x 10
-5
 - C 0.26 0.09 0.09 
18q11.2 rs299238 18.56 1.55 2.28 4.67 x 10
-5
 - T 0.75 0.45 0.45 
 
 
  
14 
 
CHAPTER IV 
 
DISCUSSION 
 
The region on chromosome 5q31.3 has been linked to PD in several previous 
studies, although this study is the first to implicate this region in the Amish population.  It 
was initially identified in an analysis of 174 families by Scott et al in 200126, and this is 
the seventh study that has implicated this region since that time.27-32 Foroud et al 
combined samples from two of these studies into one dataset for a more powered 
linkage analysis and analyzed 20 microsatellite markers across 79 cM in this region and 
found no additional evidence of linkage.33 However, these two studies each identified the 
5q peak after removing families with other PD-linked loci (parkin, chromosome 2)27,32, 
but the combined study appears to have used all families and did not condition for either 
of these two loci. Association studies published to-date have not identified a marker in 
this region.34,35 In light of previous analyses of this region, we propose that a more in-
depth study of this region in this Amish population and in other familial datasets may 
prove enlightening. There are many genes in this region. Of particular interest is 
synphilin-1 in this region36-38, which encodes a protein that interacts with alpha-synuclein, 
the main component of Lewy bodies. No study has conclusively identified an allele 
significantly associated with PD in this gene. However, most studies have analyzed 
synphilin-1 only for idiopathic PD; it is possible it could play a role in familial PD. 
The most significant linkage region we identified was on chromosome 10p12.31. 
There are several candidate genes in this region: RAB18, which has been linked to 
Warburg Micro syndrome, a developmental disorder with brain abnormalities39, 
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SLC39A12, a zinc transporter; and ITGA8, an integrin receptor expressed in the brain. 
ITGA8 was recently associated with PD in a large meta-analysis.9  
This region on chromosome 10 was also identified in an earlier linkage analysis 
we performed using microsatellite markers in a subset of the current dataset.14 It did not 
show up in the initial two-point genome-wide linkage scan we performed here, but this 
may be due to variances in coverage. The current study is the most in-depth of the 
studies we have performed for PD in this population.  
The region on chromosome 6 was only identified in multipoint linkage in this 
study because it was previously implicated in the Amish.13 This suggests that there may 
be other linked loci in this population that we missed because the two-point HLOD 
scores were not high enough to meet our criteria for follow-up. Ideally, we would analyze 
all markers across the genome that we have genotyped using multipoint linkage analysis. 
At the current point in time, however, this is not feasible due to time and computational 
requirements. 
 
Chr 
Sub-
ped 1 
Sub-
ped 2 
Sub-
ped 3 
Sub-
ped 4 
Sub-
ped 5 
Sub-
ped 6 
Sub-
ped 7 
Sub-
ped 8 
Sub-
ped 9 
Sub-
ped 10 
5 0.2904 -1.4653 0.0437 2.1626 1.5572 -0.9193 -0.1998 0 1.1993 0.9418 
6 0.2862 0.6731 -0.2512 -0.9409 -0.1427 -0.9279 1.078 0.8798 3.0017 0.9414 
10 0.2904 -0.0658 1.45 2.1581 -0.143 0.4807 1.1975 0 1.3069 -0.4649 
 
Of the 10 sub-pedigrees we analyzed in multipoint linkage analysis, between 
three and five showed evidence for linkage (LOD ≥ 0.5) in each of the four significant 
regions (Table 6, Figure 3). While there was some overlap, the set of sub-pedigrees 
linked to each region varied, and two sub-pedigrees did not link to any of the regions 
(sub-pedigrees one and six). This may be the result of the relatively small size (and 
Table 6 Peak LOD scores by sub-pedigree for the most significant multipoint linkage 
regions 
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hence power) of the sub-pedigrees, or a 
greater level of heterogeneity for PD loci 
in the Amish than previously suspected. 
Drawings of sub-pedigrees 4 and 9 with 
possible haplotypes at the peak HLOD 
scores on chromosomes 5 and 6, 
respectively, are shown in supplementary 
data (Figures 4, 5).  
 
 
 
 
 
 
 
 
 
Figure 3 LOD scores by sub-pedigree for 
with multipoint HLOD > 3.0 
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Figure 4 Possible haplotypes and co-inheritance pattern on chromosome 5 
Sub-pedigree 4 is shown with possible haplotype combinations for the peak region of 
co-inheritance on chromosome 5. The six SNPs in this haplotype are at the location of 
the maximum HLOD score. Genders have been randomized to protect privacy. 
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  Figure 5 Possible haplotypes and co-inheritance pattern on chromosome 6 
Sub-pedigree 9 is shown with possible haplotype combinations for the peak region of 
co-inheritance on chromosome 6. The four SNPs in this haplotype are at the location of 
the maximum HLOD score. Genders have been randomized to protect privacy. 
 
19 
 
CHAPTER V 
 
CONCLUSIONS 
 
Simulation studies suggest the HLOD scores we have observed on 
chromosomes 5, 6, and 10 are unlikely to be false positives. In each case, there is 
additional evidence that a true locus could exist in that region. Although we were 
somewhat surprised to find significant evidence of linkage to multiple loci, we are 
encouraged that the strong linkage signals represent true loci.  We suggest that this 
population is a prime candidate for follow-up in these regions due to the homogenous 
environment and a more homogenous genetic background than the general population. 
These benefits and the large size of the family studied may allow us to more easily 
detect and decode a true effect in these regions. We suggest an in-depth study of the 
Amish population particularly to investigate the importance of chromosome 5q31 as a 
risk locus, as this is a more genetically and environmentally homogenous study 
population and may lead to more conclusive decisions in this region. 
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